Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Linear Growth”

220 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 220 results

Testing effectiveness (Phase 2)UnknownNCT05548348
What this trial is testing

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Who this might be right for
Non-small Cell Lung CancerEGFR G719XEGFR L861Q+1 more
Chongqing University Cancer Hospital 30
Large-scale testing (Phase 3)Looking for participantsNCT06712355
What this trial is testing

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Who this might be right for
Extensive-stage Small-cell Lung Cancer
BioNTech SE 621
Not applicableActive Not RecruitingNCT06376084
What this trial is testing

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungLung NeoplasmsRespiratory Tract Neoplasms+7 more
AstraZeneca 532
Not applicableLooking for participantsNCT04216121
What this trial is testing

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

Who this might be right for
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Universitaire Ziekenhuizen KU Leuven 39
Post-approval studies (Phase 4)UnknownNCT02414399
What this trial is testing

Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children

Who this might be right for
PneumoniaDiarrheaMalaria+3 more
University of Washington 1,400
Early research (Phase 1)Active Not RecruitingNCT04167540
What this trial is testing

GDNF Gene Therapy for Parkinson's Disease

Who this might be right for
Parkinson's Disease
Brain Neurotherapy Bio, Inc. 11
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06492317
What this trial is testing

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Who this might be right for
HER2-positive Gastric Cancer
The First Affiliated Hospital of Zhengzhou University 20
Large-scale testing (Phase 3)Study completedNCT00945698
What this trial is testing

Prevention of Linear Growth Failure in Infants and Young Children With Lipid-based Nutrient Supplements (iLiNS-DOSE)

Who this might be right for
Malnutrition
Tampere University 1,920
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06586294
What this trial is testing

Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 294
Early research (Phase 1)Looking for participantsNCT04686305
What this trial is testing

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 244
Not applicableUnknownNCT04391283
What this trial is testing

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

Who this might be right for
Carcinoma, Non-Small-Cell Lung
First Affiliated Hospital of Zhejiang University 500
Large-scale testing (Phase 3)Study completedNCT00154102
What this trial is testing

Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)

Who this might be right for
Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer
Merck KGaA, Darmstadt, Germany 1,221
Not applicableLooking for participantsNCT07143045
What this trial is testing

A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

Who this might be right for
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd. 800
Testing effectiveness (Phase 2)Ended earlyNCT00845039
What this trial is testing

Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab

Who this might be right for
Colon CancerRectal Cancer
Eli Lilly and Company 4
Not applicableStudy completedNCT03891589
What this trial is testing

Optimized Complementary Feeding With or Without Home Fortification Prevents Decrease of Micronutrient and Growth

Who this might be right for
Complementary FeedingLinear ProgrammingNutritional Status+2 more
Udayana University 215
Large-scale testing (Phase 3)Ended earlyNCT00968968
What this trial is testing

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Who this might be right for
Cancer
Novartis Pharmaceuticals 37
Testing effectiveness (Phase 2)Ended earlyNCT00807612
What this trial is testing

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Who this might be right for
Advanced Squamous Non-Small Cell Lung Cancer
NantCell, Inc. 15
Not applicableWithdrawnNCT04609800
What this trial is testing

Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.

Who this might be right for
Renal Cell Carcinoma
Ipsen
Not applicableStudy completedNCT02047903
What this trial is testing

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 161
Large-scale testing (Phase 3)Study completedNCT00982111
What this trial is testing

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

Who this might be right for
Non Small Cell Lung Cancer
Eli Lilly and Company 633
Load More Results